efegatran has been researched along with phenylalanyl-prolyl-arginine in 2 studies
| Studies (efegatran) | Trials (efegatran) | Recent Studies (post-2010) (efegatran) | Studies (phenylalanyl-prolyl-arginine) | Trials (phenylalanyl-prolyl-arginine) | Recent Studies (post-2010) (phenylalanyl-prolyl-arginine) |
|---|---|---|---|---|---|
| 43 | 3 | 0 | 19 | 0 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajusz, S | 1 |
| Bajusz, S; Barabas, E; Szell, E | 1 |
1 review(s) available for efegatran and phenylalanyl-prolyl-arginine
| Article | Year |
|---|---|
Chemistry and biology of the peptide anticoagulant D-MePhe-Pro-Arg-H (GYKI-14766).
Topics: Animals; Anticoagulants; Blood Coagulation; Fibrinolytic Agents; Molecular Structure; Oligopeptides; Thrombin | 1993 |
1 other study(ies) available for efegatran and phenylalanyl-prolyl-arginine
| Article | Year |
|---|---|
Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors.
Topics: Evaluation Studies as Topic; Fibrinolysin; Fibrinolysis; Oligopeptides; Streptokinase; Thrombin; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1993 |